Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Anhydrous, Ciprofloxacin Hydrochloride
2. Bay 09867
3. Bay-09867
4. Bay09867
5. Ciprinol
6. Cipro
7. Ciprofloxacin
8. Ciprofloxacin Hydrochloride Anhydrous
9. Ciprofloxacin Monohydrochloride Monohydrate
10. Hydrochloride Anhydrous, Ciprofloxacin
11. Hydrochloride, Ciprofloxacin
12. Monohydrate, Ciprofloxacin Monohydrochloride
13. Monohydrochloride Monohydrate, Ciprofloxacin
1. Ciprofloxacin Hcl
2. 93107-08-5
3. 86483-48-9
4. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
5. Cipro
6. Chebi:310388
7. Ciprofloxacin Hydrochloride Anhydrous
8. 0mp32mfp6c
9. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hydrochloride
10. Ciprofloxacin (monohydrochloride)
11. Bay-o-9867
12. Ciprofloxacin Hydrochloride (anh.)
13. Bay O 9867
14. Cetraxal
15. Ciprobay
16. Ciproxan
17. Ciproxin
18. Flociprin
19. Ciflox
20. Mfcd00079044
21. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hcl
22. 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic Acid;hydrochloride
23. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Xhydrochloride
24. Bay-o 9867
25. 93107-08-5 (hcl)
26. 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic Acid Hydrochloride
27. Dsstox_cid_27768
28. Dsstox_rid_82545
29. Dsstox_gsid_47788
30. Ciprofloxacin (as Hydrochloride)
31. Prestwick_67
32. 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic Acid; Hydrochloride
33. 4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinolin-7-yl)-piperazin-1-ium; Chloride
34. Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid, Monohydrochloride
35. Nsc620634
36. Ciprofloxacin Hydrochloride (anhydrous)
37. Ciprofloxacin 100 Microg/ml In Methanol
38. Ncgc00016959-01
39. Cas-93107-08-5
40. Unii-0mp32mfp6c
41. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Hydrochloride
42. 3-quiolinecarboxylic Acid
43. Ciprofloxacine Hydrochloride
44. Epitope Id:174846
45. Cambridge Id 5807784
46. Ciprofloxacini Hydrochloridum
47. Chembl1202
48. Schembl42310
49. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Monohydrochloride
50. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Monohydrochloride
51. Ciprofloxacin Hcl/lactate
52. Dtxsid1047788
53. Hy-b0356a
54. Ciprofloxacin Hydrochloride (1:x)
55. Hms1568g08
56. Bcp13634
57. Bcp14336
58. Tox21_110712
59. S5008
60. Akos005111008
61. Tox21_110712_1
62. Cs-8134
63. Ks-5012
64. Nsc-620634
65. Sb73037
66. Ncgc00016959-06
67. 3-quinolinecarboxylic Acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-, Hydrochloride
68. Ac-23972
69. Bim-0048462.p001
70. Ciprofloxacin 1000 Microg/ml In Methanol
71. Ciprofloxacin Hydrochloride [who-dd]
72. Ft-0623850
73. Ft-0623851
74. A16969
75. H10663
76. A859872
77. Q-200860
78. Q27105154
79. F0001-2378
80. Cpx; Cetraxal; Ciloxan; Cipro; Bay-09867 Hydrochloride
81. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Hcl
82. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacidxhydrochloride
83. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Hydrochloride (1:1)
Molecular Weight | 367.8 g/mol |
---|---|
Molecular Formula | C17H19ClFN3O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 367.1098973 g/mol |
Monoisotopic Mass | 367.1098973 g/mol |
Topological Polar Surface Area | 72.9 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 571 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ciprofloxacin hydrochloride |
PubMed Health | Ciprofloxacin Betaine/Ciprofloxacin Hydrochloride (By mouth) |
Drug Classes | Antibacterial |
Drug Label | Ciprofloxacin Tablets, USPis a synthetic broad spectrum antimicrobial agent for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pip... |
Active Ingredient | Ciprofloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | eq 100mg base; eq 750mg base; eq 500mg base; eq 0.3% base; eq 250mg base |
Market Status | Prescription |
Company | Watson Labs; Nexus Pharms; Ranbaxy; Ivax Sub Teva Pharms; Apotex; Bausch And Lomb; Aurobindo Pharma; Taro; Dr Reddys Labs; Unique Pharm Labs; Carlsbad; Pharmaforce; Fdc; Mylan; Hikma; Akorn |
2 of 2 | |
---|---|
Drug Name | Ciprofloxacin hydrochloride |
PubMed Health | Ciprofloxacin Betaine/Ciprofloxacin Hydrochloride (By mouth) |
Drug Classes | Antibacterial |
Drug Label | Ciprofloxacin Tablets, USPis a synthetic broad spectrum antimicrobial agent for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pip... |
Active Ingredient | Ciprofloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | eq 100mg base; eq 750mg base; eq 500mg base; eq 0.3% base; eq 250mg base |
Market Status | Prescription |
Company | Watson Labs; Nexus Pharms; Ranbaxy; Ivax Sub Teva Pharms; Apotex; Bausch And Lomb; Aurobindo Pharma; Taro; Dr Reddys Labs; Unique Pharm Labs; Carlsbad; Pharmaforce; Fdc; Mylan; Hikma; Akorn |
Treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Cytochrome P-450 CYP1A2 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Ciprofloxacin Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ciprofloxacin Hydrochloride, including repackagers and relabelers. The FDA regulates Ciprofloxacin Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ciprofloxacin Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ciprofloxacin Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ciprofloxacin Hydrochloride supplier is an individual or a company that provides Ciprofloxacin Hydrochloride active pharmaceutical ingredient (API) or Ciprofloxacin Hydrochloride finished formulations upon request. The Ciprofloxacin Hydrochloride suppliers may include Ciprofloxacin Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ciprofloxacin Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Ciprofloxacin Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Ciprofloxacin Hydrochloride DMFs exist exist since differing nations have different regulations, such as Ciprofloxacin Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ciprofloxacin Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Ciprofloxacin Hydrochloride USDMF includes data on Ciprofloxacin Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ciprofloxacin Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ciprofloxacin Hydrochloride Drug Master File in Japan (Ciprofloxacin Hydrochloride JDMF) empowers Ciprofloxacin Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ciprofloxacin Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Ciprofloxacin Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ciprofloxacin Hydrochloride Drug Master File in Korea (Ciprofloxacin Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ciprofloxacin Hydrochloride. The MFDS reviews the Ciprofloxacin Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Ciprofloxacin Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ciprofloxacin Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ciprofloxacin Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ciprofloxacin Hydrochloride suppliers with KDMF on PharmaCompass.
A Ciprofloxacin Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Ciprofloxacin Hydrochloride Certificate of Suitability (COS). The purpose of a Ciprofloxacin Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ciprofloxacin Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ciprofloxacin Hydrochloride to their clients by showing that a Ciprofloxacin Hydrochloride CEP has been issued for it. The manufacturer submits a Ciprofloxacin Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ciprofloxacin Hydrochloride CEP holder for the record. Additionally, the data presented in the Ciprofloxacin Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ciprofloxacin Hydrochloride DMF.
A Ciprofloxacin Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ciprofloxacin Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Ciprofloxacin Hydrochloride written confirmation (Ciprofloxacin Hydrochloride WC) is an official document issued by a regulatory agency to a Ciprofloxacin Hydrochloride manufacturer, verifying that the manufacturing facility of a Ciprofloxacin Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ciprofloxacin Hydrochloride APIs or Ciprofloxacin Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Ciprofloxacin Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ciprofloxacin Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ciprofloxacin Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ciprofloxacin Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ciprofloxacin Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ciprofloxacin Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ciprofloxacin Hydrochloride suppliers with NDC on PharmaCompass.
Ciprofloxacin Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ciprofloxacin Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ciprofloxacin Hydrochloride GMP manufacturer or Ciprofloxacin Hydrochloride GMP API supplier for your needs.
A Ciprofloxacin Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Ciprofloxacin Hydrochloride's compliance with Ciprofloxacin Hydrochloride specifications and serves as a tool for batch-level quality control.
Ciprofloxacin Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Ciprofloxacin Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ciprofloxacin Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Ciprofloxacin Hydrochloride EP), Ciprofloxacin Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ciprofloxacin Hydrochloride USP).
LOOKING FOR A SUPPLIER?